Heroin on trial: Systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction

British Journal of Psychiatry

Volumn 207, Issue 1, 2015, Pages 5-14

  Strang, John ^a,b   Groshkova, Teodora ^a,c   Uchtenhagen, Ambros ^d   Van Den Brink, Wim ^e   Haasen, Christian ^f   Schechter, Martin T ^g   Lintzeris, Nick ^h   Bell, James ^b   Pirona, Alessandro ^c   Oviedo Joekes, Eugenia ^g   Simon, Roland ^c   Metrebian, Nicola ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION   (Portugal)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e AMSTERDAM INSTITUTE FOR ADDICTION RESEARCH   (Netherlands)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h University of Sydney   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMORPHINE; HYDROMORPHONE; METHADONE;

ARTICLE; CLINICAL PRACTICE; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; HEROIN DEPENDENCE; HUMAN; META ANALYSIS; METHADONE TREATMENT; MORTALITY; PATIENT SATISFACTION; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELF REPORT; SUPERVISED INJECTABLE HEROIN TREATMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; OPIATE SUBSTITUTION TREATMENT;

HEROIN; HEROIN DEPENDENCE; HUMANS; METHADONE; OPIATE SUBSTITUTION TREATMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84937211897     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.114.149195     Document Type: Article

References (68)

1. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000; 284: 1689-95.
2. Strang J, Babor T, Caulkins J, Fischer B, Foxcroft D, Humphreys K. Drug policy and the public good: evidence for effective interventions. Lancet 2012; 379: 71-83.
3. Bammer G, Dobler-Mikola A, Fleming PM, Strang J, Uchtenhagen A. The heroin prescribing debate: integrating science and politics. Science 1999; 284: 1277-8.
4. Hartnoll RL, Mitcheson MC, Battersby A, Brown G, Ellis M, Fleming P, et al. Evaluation of heroin maintenance in controlled trial. Arch Gen Psychiatry 1980; 37: 877-84.
5. Perneger TV, Giner F, del RM, Mino A. Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ 1998; 317: 13-18.
6. Musto D. The American Disease: Origins of Narcotic Control. Oxford University Press, 1999.
7. Strang J, Gossop M. Heroin Addiction and the British System: Treatment and Other Responses, vol. 2. Routledge, 2004.
8. Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet 2001; 358: 1417-23.
9. Uchtenhagen A. Narcotics Prescription for Heroin Addicts: Main Results of the Swiss National Cohort Study (Medical Prescription of Narcotics). Karger, 1998.
10. Uchtenhagen A. Heroin-assisted treatment in Switzerland: a case study in policy change. Addiction 2010; 105: 29-37.
11. Wright NM, Tompkins CN. Supervised injecting centres. BMJ 2004; 328: 100-2.
12. Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev 2011; 12: CD003410.
13. van den Brink W, Hendriks VM, Blanken P, Koeter MW, van Zwieten BJ, van Ree JM. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ 2003; 327: 310.
14. March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F. Controlled trial of prescribed heroin in the treatment of opioid addiction. J Subst Abuse Treat 2006; 31: 203-11.
15. Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry 2007; 191: 55-62.
16. Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med 2009; 361: 777-86.
17. Strang J, Metrebian N, Lintzeris N, Potts L, Carnwath T, Mayet S, et al. Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet 2010; 375: 1885-95.
18. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2009). The Cochrane Collaboration, 2008.
19. Byford S, Barrett B, Metrebian N, Groshkova T, Cary M, Charles V, et al. Cost-effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction. Br J Psychiatry 2013; 203: 341-9.
20. Groshkova T, Metrebian N, Hallam C, Charles V, Martin A, Forzisi L, et al. Treatment expectations and satisfaction of treatment-refractory opioid-dependent patients in RIOTT, the Randomised Injectable Opiate Treatment Trial, the UK's first supervised injectable maintenance clinics. Drug Alcohol Rev 2013; 32: 566-73.
21. Verthein U, Schafer I, Degkwitz P. Social integration after 4 years of heroin-assisted treatment. Rehabilitation 2013; 52: 243-50.
22. Vogel M, Knopfli B, Schmid O, Prica M, Strasser J, Prieto L, et al. Treatment or "high": benzodiazepine use in patients on injectable heroin or oral opioids. Addict Behav 2013; 38: 2477-84.
23. Nosyk B, Guh DP, Bansback NJ, Oviedo-Joekes E, Brissette S, Marsh DC, et al. Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. Can Med Assoc J 2012; 184: E317-28.
24. Marchand KI, Oviedo-Joekes E, Guh D, Brissette S, Marsh DC, Schechter MT. Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency. BMC Health Serv Res 2011; 11: 174-84.
25. Verthein U, Haasen C, Reimer J. Switching from methadone to diamorphine: 2-year results of the German heroin-assisted treatment trial. Subst Use Misuse 2011; 46: 980-91.
26. Blanken P, Hendriks VM, van Ree JM, van den Brink W. Outcome of long-term heroin-assisted treatment offered to chronic, treatment-resistant heroin addicts in the Netherlands. Addiction 2010; 105: 300-8.
27. Blanken P, van den Brink W, Hendriks VM, Huijsman IA, Klous MG, Rook EJ, et al. Heroin-assisted treatment in the Netherlands: History, findings, and international context. Eur Neuropsychopharmacol 2010; 20 (suppl 2): S105-158.
28. Eiroa-Orosa Haasen C, Verthein U, Dilg C, Schafer I, Reimer J. Benzodiazepine use among patients in heroin-assisted vs methadone maintenance treatment. Findings of the German randomised controlled trial. Drug Alcohol Depend 2010; 112: 226-33.
29. Haasen C, Verthein U, Eiroa-Orosa Schafer I, Reimer J. Is heroin-assisted treatment effective for patients with no previous maintenance treatment? Results from a German randomised controlled trial. Eur Addict Res 2010; 16: 124-30.
30. Karow A, Reimer J, Schafer I, Krausz M, Haasen C, Verthein U. Quality of life under maintenance treatment with heroin versus methadone in patients with opioid dependence. Drug Alcohol Depend 2010; 112: 209-15.
31. Lasnier B, Brochu S, Boyd N, Fischer B. A heroin prescription trial: case studies from Montreal and Vancouver on crime and disorder in the surrounding neighbourhoods. Int J Drug Policy 2010; 21: 28-35.
32. Miller P, McKenzie S, Lintzeris N, Martin A, Strang J. The community impact of RIOTT, a medically supervised injectable maintenance clinic in South London. Mental Health Subst Use Dual Diagn 2010; 3: 248-59.
33. Oviedo-Joekes E, March JC, Romero M, Perea-Milla E. The Andalusian trial on heroin-assisted treatment: a 2 year follow-up. Drug Alcohol Rev 2010; 29: 75-80.
34. Oviedo-Joekes E, Guh D, Brissette S, Marchand K, Marsh D, Chettiar J, et al. Effectiveness of diacetylmorphine versus methadone for the treatment of opioid dependence in women. Drug Alcohol Depend 2010; 111: 50-7.
35. Oviedo-Joekes E, Guh D, Marsh DC, Brissette S, Nosyk B, Krausz M, et al. Characteristics and response to treatment among aboriginal people receiving heroin-assisted treatment. Can J Public Health 2010; 101: 210-2.
36. Scafer I, Eiroa-Oroa FJ, Verthein U, Dilg C, Haasen C, Reimer J. Effects of psychiatric comorbidity on treatment outcomes in patients undergoing diamorphine or methadone maintenance. Psychopathology 2010; 43: 88-95.
37. Haasen C. Gesundheitsökonomische Begleitforschung (Unpublished Economic Evaluation Report, German Trial). 2009.
38. Perea-Milla E, Aycaguer LCS, Cerda JCM, Saiz FG, Rivas-Ruiz F, Danet A, et al. Efficacy of prescribed injectable diacetylmorphine in the Andalusian trial: Bayesian analysis of responders and non-responders according to a multi domain outcome index. Trials 2009; 10: 70-6.
39. Haasen C, Eiroa-Orosa Verthein U, Soyka M, Dilg C, Schafer I, et al. Effects of heroin assisted treatment on alcohol consumption. Findings of the German randomised controlled trial. Alcohol 2009; 43: 259-64.
40. Romo N, Poo M, Ballesta R. From illegal poison to legal medicine: a qualitative research in a heroin-prescription trial in Spain. Drug Alcohol Rev 2009; 28: 186-95.
41. Miller P, Forzisi L, Lintzeris N, Zador D, Metrebian N, Strang J. Groin injecting in injectable opioid treatment service users in South London. Addict Res Theory 2009; 17: 381-9.
42. Verthein U, Bonorden-Kleij K, Degkwitz P, Dilg C, Kohler WK, Passie T, et al. Long-term effects of heroin-assisted treatment in Germany. Addiction 2008; 103: 960-6.
43. Dursteler-Macfarland KM, Stohler R, Moldovanyi A, Rey S, Basdekis R, Gschwend P, et al. Complaints of heroin-maintained patients - a survey of symptoms ascribed to diacetylmorphine. Drug Alcohol Depend 2006; 81: 231-9.
44. Dijkgraaf MG, van der Zanden BP, de Borgie CA, Blanken P, van Ree JM, van den Brink W. Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. BMJ 2005; 330: 1297.
45. Rehm J, Frick U, Hartwig C, Gutzwiller P, Uchtenhagen A. Mortality in heroin-assisted treatment in Switzerland 1994-2000. Drug Alcohol Depend 2005; 79: 137-43.
46. Guttinger F, Gschwend P, Schulte B, Rehm J, Uchtenhagen A. Evaluating long-term effects of heroin-assisted treatment: the results of a 6-year follow-up. Eur Addict Res 2003; 9: 73-9.
47. Oviedo-Joekes E, Guh D, Brissette S, Oviedo-Joekes E, Guh D, Brissette S, et al. Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot study. J Subst Abuse Treat 2010; 38: 408-11.
48. Paterson S, Lintzeris N, Mitchell TB, Cordero R, Nestor L, Strang J. Validation of techniques to detect illicit heroin use in patients prescribed pharmaceutical heroin for the management of opioid dependence. Addiction 2005; 100: 1832-39.
49. Sterne JAC, Harbord RM. Funnel plots in meta-analysis. Stata J 2004; 4: 127-41.
50. United Nations Single Convention on Narcotic Drugs. UN, 1961.
51. United Nations Convention on Psychotropic Substances. UN, 1971.
52. Rolleston Report: Report of the Departmental Committee on Morphine and Heroin Addiction. Ministry of Health, 1926.
53. Interdepartmental Committee on Drug Addiction (Brain Committee). Drug Addiction, Second Report. Her Majesty's Stationery Office, 1965.
54. Federal Law on Narcotics and Psychotropic Substances. Revision 30.11.2008. Department of Health, 2008.
55. Pfeiffer-Gerschel T, Kipke I, Floter S, Lieb C, Raiser P. German National Report on Drugs to the European Monitoring Centre for Drugs and Drug Addiction. Munich, Germany, 2009.
56. Order 29.5.2008 of the Ministrz of Health and Prevention. Denmark, 2008.
57. Gartry CC, Oviedo-Joekes E, Laliberte N, Schechter MT. NAOMI: the trials and tribulations of implementing a heroin assisted treatment study in North America. Harm Reduct J 2009; 6: 2.
58. Ministerio De La Presidencia. Real Decreto 75/1990 De 19 De Enero, Por El Que Se Regulan Los Tratamientos Con Opiáceos De Las Personas Dependientes De Los Mismos. Boletín Oficial Del Estado Del 11 De Abril 1990. Ministerio de la Presidencia, 1990.
59. Ministerio De La Presidencia. Real Decreto 5/1996 De 15 De Enero, Sobre Modificación Del Real Decreto 75/1990, De 19 De Enero, Por El Que Se Regulan Los Tratamientos Con Opiáceos De Personas Dependientes De Los Mismos, Y De Ampliación De Su Anexo. Boletín Oficial Del Estado Del 20 De Febrero 1996. Minesterio de la Presidencia, 1996.
60. Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin dependents. Cochrane Database Syst Rev 2005; 2: CD003410.
61. Clark S. RIOTT, Recovery and Me: A Personal Story from Our New Members' Council Recruit. SLaM news, 24-26, 2010.
62. Hannah, X. I predict a RIOTT. Black Poppy 2012: 14: 27-8.
63. Strang J, Groshkova T, Metrebian N. New heroin-assisted treatment: recent evidence and current practices of supervised injectable heroin treatment in Europe and beyond (EMCDDA Insight): 143-144. European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal, 2012 (http://www.emcdda.europa.eu/publications/insights/heroin-assisted-treatment).
64. Department of Health (DoH). Invitation to tender: the piloting of supervised injectable Opioid Treatment. DoH, 2012 (https://www.gov.uk/government/news/invitation-to-tender-the-piloting-of-supervised-injectable-opioidtreatment).
65. MacCoun R, Reuter P. Drug War Heresies: Learning from Other Vices, Times and Places. Cambridge University Press, 2001.
66. Schechter M. Science, ideology, and needle exchange programs. Ann Am Acad Political Social Sci 2002; 582: 94-101.
67. Strang J. Harm reduction for drug users: exploring the dimensions of harm, their measurement and the strategies for reduction. AIDS Public Policy J 1992; 7: 145-52.
68. Bammer G. The act heroin trial: intellectual, practical and political challenges. Drug Alcohol Rev 1997; 16: 287-96.